NCT00586508 - Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Recurrent Glioblastoma

Interventions

DRUG

enzastaurin

1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).

DRUG

bevacizumab

10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).

DRUG

Enzyme-inducing antiepileptic drugs (EIAED)

Administered orally

DRUG

Non-enzyme inducing antiepileptic drugs (NEIAED)

Administered orally

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda